Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Leukemia 20Breast Neoplasms 9Lymphoma 7Lung Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Sarcoma 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Precancerous Conditions 4Lymphoma, Follicular 4Squamous Cell Carcinoma of Head and Neck 3Prostatic Neoplasms 3Myelodysplastic Syndromes 3Multiple Myeloma 3Lymphoma, Large-Cell, Anaplastic 3Leukemia, Myeloid, Acute 3Head and Neck Neoplasms 3Gliosarcoma 3Glioblastoma 3Esophageal Neoplasms 3Congenital Abnormalities 3Central Nervous System Neoplasms 3Adenocarcinoma Of Esophagus 3Wilms Tumor 2Stomach Neoplasms 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Neoplasms, Plasma Cell 2Myeloproliferative Disorders 2Myelodysplastic-Myeloproliferative Diseases 2

Interventions

eltrombopag 8romiplostim 5Cytarabine 4Filgrastim 3Etoposide 3Daunorubicin 3Carboplatin 3oprelvekin 2fludarabine phosphate 2avatrombopag 2Thrombopoietin 2Radiotherapy 2Peripheral Blood Stem Cell Transplantation 2Lenalidomide 2Interleukin-11 2Ifosfamide 2Doxorubicin 2Cyclosporine 2Busulfan 2sargramostim 1ofatumumab 1lusutrombopag 1leridistim 1bryostatin 1 1angiotensin I (1-7) 1alvocidib 1Vitamin E 1Vitamin B 12 1Vincristine 1Tranexamic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Thrombocytopenia × Microarray Analysis × Clear all
NCT01165996 2019-03-04

Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome

Case Comprehensive Cancer Center

Phase 1/2 Completed
25 enrolled 13 charts
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Thrombocytopenia, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡